ArticleCurrent drug discovery technologies2025
Article in Current drug discovery technologies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antimicrobial peptides-based strategies at the frontline in battling the escalating menace of methicillin-resistant Staphylococcus aureus biofilms.European journal of microbiology & immunology · 2026Review
- Targeting the bacterial stringent response to combat human pathogens.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMethicillin-resistant
methodsThis condition has prompted the exploration of various novel approaches and methodologies to combat MRSA infections. Among these, peptide therapeutics stand out as a promising nextgeneration treatment option. In this study, ninety antimicrobial peptides were sourced from the antimicrobial peptide database and the other sixty-one peptide sequences were designed using the Pepdraw server. These peptide sequences were screened out using different RESULTS AND DISCUSSION: Out of 151 peptide sequences, Pantocin wh-1 emerged as the most promising drug candidate. Both molecular interaction studies and molecular dynamics simulations demonstrated positive results.
conclusionPeptide therapeutics is a novel approach researchers are presently exploring as it provides prompt significant results and promotes a new insight towards dealing with conditions like MDR. Pantocin wh-1 is a peptide drug currently listed as an accessible anti-tuberculosis peptide, and this study suggests the repurposing of this drug as a viable treatment option for MRSA infections.
Indexed as
Identifiers
39949095What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.